首页 / 院系成果 / 成果详情页

Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis 期刊论文

编号：

8252d189-cc86-4bc7-91be-555e4d24bbe8
作者：

Yang, Lili(杨丽丽)#^[1]Guo, Gongliang^[2];Sun, Liqun^[3];Li, Chenhao(李晨昊)^[4]Zhang, Haipeng(张海鹏)*^[5]
语种：

英文
期刊：

ONCOTARGET ISSN：1949-2553 2017 年 8 卷 35 期 (59867 - 59877) ; AUG 29
收录：
关键词：

ovarian neoplasm network meta-analysis carboplatin pegylated liposomal doxorubicin paclitaxel
摘要：

Background: Ovarian neoplasm is a kind of high risky cancer among female. This paper assessed the efficacy and safety of twelve therapies and figured out the superior chemotherapeutic drug for ovarian cancer through network meta-analysis (NMA).
Method: Eligible randomized controlled trials (RCTs) were retrieved from electronic databases. Primary outcomes concerning efficacy, overall survival (OS) and progression-free survival (PFS), were presented as hazard ratio (HR) and the associated 95% credible interval(CrI), while outcomes concerning safety were assessed by odds ratio (OR) and the corresponding 95% CrI. Surface under the cumulative ranking curve (SUCRA) was calculated under each survival and safety outcome in order to show the rankings of tested therapies.
Result: Electronic databases such as PubMed and Embase were searched to finally obtain 19 eligible studies of 16290 patients. In accordance of primary outcomes, when it came to 3-y PFS, paclitaxel/epirubicin/carboplatin (Pa/E/Ca) and pegylated liposomal doxorubicin/paclitaxel/carboplatin (PLD/Pa/Ca) were preferred compared to carboplatin (Ca )(HR = 0.80, 95% CrI = 0.67-0.96; HR = 0.83, 95% CrI = 0.69-0.99). According to 5y-PFS, Pa/E/Ca was notably better than Ca (HR = 0.80, 95% CrI = 0.650.99). As to adverse effects, Ca was superior to Pa/E/Ca in neuropathy (HR=0.05, 95% CrI=0.02-0.19). Pa/E/Ca showed high rankings in 3y-PFS (SUCRA=0.749), 5y-OS (SUCRA=0.738) and 5y-PFS (SUCRA=0.798) while (PLD/Pa/Ca) in 3y-OS(SUCRA=0.737), 5y-OS (SUCRA=0.687) and 5y-PFS (SUCRA=0.712). Besides, Pa/E/Ca ranked the third with a SUCRA of 0.661 in neutropenia.
Conclusion: PLD/Pa/Ca, PLD/Ca and Pa/E/Ca are highly recommended as potential therapeutically choices for patients with ovarian cancer. But considering the lack of safety data for PLD/Pa/Ca, this intervention should be taken with caution.
推荐引用方式
GB/T 7714：

Yang Lili,Guo Gongliang,Sun Liqun, et al. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis [J].ONCOTARGET,2017,8(35):59867-59877.
APA：

Yang Lili,Guo Gongliang,Sun Liqun,Li Chenhao,&Zhang Haipeng.(2017).Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis .ONCOTARGET,8(35):59867-59877.
MLA：

Yang Lili, et al. "Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis" .ONCOTARGET 8,35(2017):59867-59877.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：90  下载次数：0

分享到：

浏览次数：90

下载次数：0

打印次数：0